Sever Pharma Solutions Announces Commercialization of New Aseptic Fill and Finish Line for Prefilled Syringes in Malmö, Sweden


MALMÖ, SWEDEN– Sever Pharma Solutions, a leading CDMO, proudly announces the commercialization of its new state-of-the-art aseptic fill and finish line for prefilled syringes, capable to handle high-potent and cytotoxic injectable drugs at its Malmö facility. This advanced production line, which has been inspected and GMP certified by the Swedish Health authorities, is now operational, and ready to serve our clients globally. The newly launched aseptic filling line incorporates automated visual inspection for enhanced quality control and the state-of-the-art line complies with the highest standards for guaranteeing   product quality and safety.

The line is specifically designed for prefilled syringes, and seamlessly integrates with Sever Pharma Solutions’ existing assembly capabilities for auto-injectors. This integration provides pharmaceutical companies with a comprehensive and efficient end-to-end manufacturing solution, accelerating time-to-market while maintaining exceptional quality standards.

“We’re delighted to announce the commercialization and operational start of our aseptic fill and finish line for prefilled syringes in the 1mL Long format,” said Frederik Hultenius, VP of Operations at Sever Pharma Solutions. “This significant milestone underscores our continued commitment to innovation and excellence. Our clients can now benefit from enhanced efficiency, reduced timelines, and consistently high-quality drug products.”

This development reaffirms Sever Pharma Solutions’ dedication to advancing pharmaceutical manufacturing capabilities, positioning the company as a trusted global partner in drug development and manufacturing.

For further information on Sever Pharma Solutions and its comprehensive capabilities, please visit www.severpharmasolutions.com or contact BD@severpharmasolutions.com.